CHOP Researchers Find NTRK Fusions More Common than Expected in Pediatric Tumors

CHOP Researchers Find NTRK Fusions More Common than Expected in Pediatric Tumors
--Study highlights wide range of pediatric cancers in which NTRK fusions are more likely to occur, which could help prioritize testing for targeted treatment with FDA-approved TRK inhibitors--
News provided by
Share this article
Share this article
PHILADELPHIA, Jan. 15, 2021 /PRNewswire/ -- In a large study of pediatric cancer patients, researchers from Children's Hospital of Philadelphia (CHOP) have analyzed the frequency, fusion partners, and clinical outcome of neurotrophic tyrosine receptor kinase (NTRK) fusions, which are clinical biomarkers that identify patients suitable for treatment with FDA-approved TRK inhibitors. The researchers found that NTRK fusions are more common in pediatric tumors and also involve a wider range of tumors than adult cancers, information that could help prioritize screening for NTRK fusions in pediatric cancer patients who might benefit from treatment with TRK inhibitors.

Related Keywords

Philadelphia ,Pennsylvania ,United States ,Ashley Moore ,Marilynm Li ,Division Of Genomic Diagnostics ,Vice Chief ,Genomic Diagnostics ,Cancer Genomic Diagnostics ,Fusion Partners ,Clinical Outcome ,Children 39s Hospital Of Philadelphia ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Children ,Surveys ,Polls And Research ,பிலடெல்பியா ,பென்சில்வேனியா ,ஒன்றுபட்டது மாநிலங்களில் ,ஆஷ்லே மூர் ,துணை தலைமை ,இணைவு கூட்டாளர்கள் ,மருத்துவ ஔட்‌கம் ,ஆரோக்கியம் பராமரிப்பு ஆம்ப் மருத்துவமனைகள் ,மருத்துவ மருந்துகள் ,குழந்தைகள் ,ஆய்வுகள் ,போல்ஸ் மற்றும் ஆராய்ச்சி ,